A high BMI may qualify you for a vaccine, but may not mean you re unhealthy Here s how to check ktvz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ktvz.com Daily Mail and Mail on Sunday newspapers.
Read More
Obesity also increases the risk of having a more severe reaction to Covid-19, he said.
There are some rare cases when a healthy person reports an unhealthy BMI number, according to Rosen. Weight trainers and people with athletic builds have a lot of muscle on them, which could create a high BMI number, said Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women s Hospital. A lot of football players have a BMI of 30, 35 or even 40, but they re all muscle so they re extremely healthy, Apovian said.
If you re unsure of whether your high BMI number is due to fat or muscle, Apovian recommended seeing a weight loss specialist to have more specific tests done.
A high BMI may qualify you for a vaccine, but may not mean you re unhealthy Here s how to check kvia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kvia.com Daily Mail and Mail on Sunday newspapers.
“People are crying. They are anxious,” said Sigsbee, a member of the Cape Cod Medical Reserve Corps.
When will I get my vaccine?
The No. 1 question of tens of thousands of callers to the help line is, “When will I get my vaccine?” she said.
A limited number of vaccines going to Barnstable County’s elderly residents, combined with a state registration system known for booting people off the site as soon as they think they are closing in on an appointment, has filled help line callers with fear and frustration.
They want to know, “Will I be left behind?” Sigsbee said.
Feb 11, 2021 11:08am
Novo Nordisk estimates that only 10% of 650 million people with obesity currently seek medical treatment, leaving the market wide open for its drug semaglutide. (Creative Commons CC0)
Novo Nordisk has taken one step forward in its ambition to move its Type 2 diabetes drug semaglutide into the giant and largely untapped obesity market. And despite the failure of past obesity drugs not to mention lackluster sales of Novo’s own weight loss product Saxenda the company’s executives now have even more reason to be optimistic.
Data from a phase 3 trial released Wednesday night showed that one-third of patients taking semaglutide, a GLP-1 agonist, lost more than 20% of their body weight during the 68-week trial. The average participant lost more than 33 pounds, and many saw improvements in risk factors for diabetes and heart disease, according to University College London, one of the principle trial sites. The study was published in the New England Journal of Medi